Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937307 · ClinicalTrials.gov registry record · Phase 2
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
A Phase 2 study of Acute Kidney Injury and Cirrhosis, sponsored by Giuseppe Cullaro, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06937307 is a Phase 2 study of Acute Kidney Injury and Cirrhosis that is actively recruiting participants, run by Giuseppe Cullaro, MD. The registered enrollment target is 75 participants, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06937307, a Phase 2 study of Acute Kidney Injury and Cirrhosis, is actively recruiting participants, sponsored by Giuseppe Cullaro, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Droxidopa is an oral medication that may help raise blood pressure without requiring intensive care or invasive treatments. The study will compare droxidopa to a placebo (inactive pill) in 75 people hospitalized with cirrhosis and kidney injury. Participants will take either droxidopa or placebo pills for 28 days and be monitored for an additional 30 days. Researchers will measure changes in blood pressure and kidney function to determine if droxidopa is effective and safe for these patients. This research could identify a new treatment option for a serious complication of liver disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Droxidopa capsules
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06937307
The ClinicalTrials.gov registry entry for NCT06937307 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (97% lower). The listed sponsor is Giuseppe Cullaro, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06937307 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06937307 about?
NCT06937307 is a clinical study titled "Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury". This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Drox...
What is the current status of trial NCT06937307?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2025-05-27. Estimated completion is 2027-12-31.
What conditions does trial NCT06937307 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver.
What interventions are being tested in trial NCT06937307?
The interventions under investigation include: Placebo (OTHER), Droxidopa capsules (DRUG).
Who is sponsoring clinical trial NCT06937307?
This trial is sponsored by Giuseppe Cullaro, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937307 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.